Clinical trials: Dendritic Cell
Asthma
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma
The aim of this study is to evaluate the expression of IgE high affinity receptors (the part of the cell associated with allergic response) in patients suffering from uncontrolled severe asthma despite long term treatment with…
- Trial name
- NCT00454051
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Melanoma
Dendritic Cell Based Therapy of Malignant Melanoma
The aim of the study is to show if vaccination with autologous dendritic cells pulsed with peptides or tumor lysate in combination with adjuvant cytokines and Cyclophosphamide can induce a measurable immune response in patients…
- Trial name
- NCT00197912
- Testing
- tumor antigen loaded autologous dendritic cells
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Herlev Hospital
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate…
- Trial name
- OU-SCC-EXCITE (NCT05806814)
- Testing
- Sipuleucel-T
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Oklahoma
Refractory Tumor, Solid Tumor
Neoantigen Derived DCs as Cancer Treatment
Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit.
- Trial name
- NCT05767684
- Testing
- Dendritic Cell Vaccine, Lenvatinib, Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- National Health Research Institutes, Taiwan
Malignant Melanoma Stage IV
Combined Modality Treatment for Patients With Stage IV Melanoma
The purpose of this study is to test a combined treatment using cyclophosphamide and a novel dendritic cell vaccine in patients with Stage IV melanoma.
- Trial name
- NCT00313235
- Testing
- DC Vaccine and Cyclophosphamide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Baylor Research Institute
Brain Stem Glioma, Glioblastoma
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
The purpose of the Dendritic Cell Immunotherapy study for patients with glioblastoma and/or brainstem glioma is to determine whether in patients with malignant brain tumors, dendritic cells injected peripherally can reactivate…
- Trial name
- NCT00576641
- Testing
- autologous dendritic cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer Female, Early-stage Breast Cancer
Intratumoral TriMix Injections in Early Breast Cancer Patients
Patients with early breast cancer and accessible tumor lesions (1.00 to 10 ml volume) that are eligible to either surgical removal of their tumor or neoadjuvant chemotherapy will be injected with the IMP.
- Trial name
- TMBA (NCT03788083)
- Testing
- Trimix
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Universitair Ziekenhuis Brussel
Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.
- Trial name
- NCT02638857
- Testing
- TACE, Dendritic Cell, lipiodol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Acute Myeloid Leukemia, Myelodysplasia
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in adults with high-risk hematopoietic malignancies. A novel myeloablative preparative regimen will be used.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00514722
- Testing
- umbilical cord stem cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Francisco
Prostate Cancer Indications
Prostate Cancer Vaccines
Tumor antigens are protein fragments produced by cancer cells carrying genetic mutations, and many tumor antigens are similar to normal protein antigens, making them unrecognizable by the immune system.
- Trial name
- NCT07068555
- Testing
- Immunomodulatory DC vaccines to target prostate cancer
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Rhinosinusitis
Investigate the Role of microRNA in Chronic Rhinosinusitis From DC-Th Axis
This study aimed to evaluate the upstream events of Th17/Treg imbalance in CRS and their immune regulatory factors. Then the investigators aimed to explore the regulatory role of miRNA on DC-Th axis and its dysfunction in the…
- Trial name
- ITROMICRFDTA (NCT02325596)
- Testing
- miRNA mimics or inhibitors
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Recurrent Ovarian Cancer
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
Effective treatments are desperately needed for ovarian cancer patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to ovarian cancer patients.
- Trial name
- NCT05270720
- Testing
- dendritic cell
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Second University Hospital
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD
Pancreatic Cancer
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU)…
- Trial name
- PancVax (NCT02548169)
- Testing
- DC Vaccine + Standard of Care Chemotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Baylor Research Institute
Uveal Melanoma
Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.
- Trial name
- NCT01983748
- Testing
- Autologous Dendritic Cells loaded with autologous Tumor RNA
- Where
- 8 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Erlangen
Kidney Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
- Trial name
- NCT00005816
- Testing
- therapeutic autologous dendritic cells, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Mesothelioma, Malignant, PD-L1 Negative
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label, phase 1b clinical trial.
- Conditions
- Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive Disease
- Trial name
- MESOVAX (NCT03546426)
- Testing
- Pembrolizumab, Autologous dendritic cells, Interleukin-2
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Chronic Hepatitis C Infection
The Role of Dendritic Cells in Hepatitis C Infection
The role of the dendritic cells, the most potent antigen presenting cells, in the establishment of chronic hepatitis C is not established.
- Trial name
- NCT00723242
- Testing
- Viraferon-peg and Rebetol
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University College, London
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium